| 摘要 |
Mammalian patients suffering from post-wounding trauma, or about to or likel y to suffer such trauma (by surgical treatment, or by suffering unanticipated accidental injuries, battle injuries or the like) are treated to lessen the severity of or accelerate the recovery from such subsequently sustained trauma, by administering to the patient immune system-modifying entities, ea ch comprising a body of a size similar to an apoptotic mammalian cell or apoptotic body, and having exposed on its surface phospho-amino acid groups, the entities being capable of being taken up by cells of the patient=s immun e system with accompanying beneficial effects including inhibition of pro- inflammatory cytokines and/or promotion of anti-inflammatory cytokines. The entities may be phosphatidylserine-presenting liposomes or natural products, beads carrying phospho-serine or phosphatidylserine side groups, apoptotic cells or apoptotic bodies, generally of size 50 nanometers to 500 microns, a nd administered to contact a patient=s immune system (e.g. intramuscularly) in amounts which affect but do not overwhelm the patient=s immune system.</SDOA B>
|
